Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future.
作者信息
Porcari Aldostefano, Sinagra Gianfranco, Gillmore Julian D
机构信息
Division of Medicine, National Amyloidosis Centre, University College London, London, United Kingdom.
Centre for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy.
出版信息
Front Med (Lausanne). 2023 Jul 17;10:1232212. doi: 10.3389/fmed.2023.1232212. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future.社论：心脏淀粉样变性的进展与预测：未解之谜与未来挑战
Front Med (Lausanne). 2023 Jul 17;10:1232212. doi: 10.3389/fmed.2023.1232212. eCollection 2023.
2
Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.心脏淀粉样变性中轻链和转甲状腺素相关分类的预后影响：系统评价和荟萃分析。
Hellenic J Cardiol. 2019 Nov-Dec;60(6):375-383. doi: 10.1016/j.hjc.2019.01.015. Epub 2019 Feb 8.
3
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.心脏淀粉样变性的治疗现状与未来方向及预后
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
4
Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.转甲状腺素相关与轻链心脏淀粉样变性的左心室结构和功能。
Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.
5
Cardiac amyloidosis: updates in diagnosis and management.心脏淀粉样变性：诊断与治疗进展。
Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23.
6
[Cardiac amyloidosis].[心脏淀粉样变性]
Ann Pathol. 2021 Feb;41(1):25-37. doi: 10.1016/j.annpat.2020.11.010. Epub 2021 Jan 6.
7
Targeted treatments of AL and ATTR amyloidosis.针对 AL 和 ATTR 淀粉样变性的靶向治疗。
Heart Fail Rev. 2022 Sep;27(5):1587-1603. doi: 10.1007/s10741-021-10180-z. Epub 2021 Nov 16.
8
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.心脏淀粉样变：被忽视、被低估且可治疗。
Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140.
9
Evidence of Concurrent Light Chain and Transthyretin Cardiac Amyloidosis in 2 Patients.2例患者并发轻链和转甲状腺素蛋白心脏淀粉样变性的证据
JACC CardioOncol. 2020 Mar 17;2(1):127-130. doi: 10.1016/j.jaccao.2020.01.001. eCollection 2020 Mar.
10
Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?病例报告：两姐妹均患有轻链型心脏淀粉样变性，这仅仅是巧合吗？
Eur Heart J Case Rep. 2022 Feb 17;6(2):ytac084. doi: 10.1093/ehjcr/ytac084. eCollection 2022 Feb.
本文引用的文献
1
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.~99mTc 标记骨闪烁显像在疑似心脏淀粉样变性中的应用。
Eur Heart J. 2023 Jun 25;44(24):2187-2198. doi: 10.1093/eurheartj/ehad139.
2
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis.转甲状腺素蛋白淀粉样变性病男女患者的左心室壁厚度与心脏疾病严重程度
Eur J Heart Fail. 2023 Apr;25(4):510-514. doi: 10.1002/ejhf.2824. Epub 2023 Mar 15.
3
Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.遗传性与野生型转甲状腺素蛋白淀粉样心肌病老年患者的患病率、特征及预后
Eur J Heart Fail. 2023 Apr;25(4):515-524. doi: 10.1002/ejhf.2776. Epub 2023 Jan 30.
4
Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.转甲状腺素蛋白淀粉样变性心肌病患者的性别差异——从诊断到预后。
Eur J Heart Fail. 2022 Dec;24(12):2355-2363. doi: 10.1002/ejhf.2646. Epub 2022 Aug 16.
5
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: State-of-the-Art Review.心脏病专家的AL淀粉样变性：认识、诊断及未来展望：最新综述
JACC CardioOncol. 2022 Nov 15;4(4):427-441. doi: 10.1016/j.jaccao.2022.08.009. eCollection 2022 Nov.
6
Comparison of different technetium-99m-labelled bone tracers for imaging cardiac amyloidosis.用于心脏淀粉样变性成像的不同锝-99m标记骨显像剂的比较。
Eur J Prev Cardiol. 2023 Feb 14;30(3):e4-e6. doi: 10.1093/eurjpc/zwac237.
7
Transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变性。
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. doi: 10.1093/cvr/cvac119.
8
Value of the HFA-PEFF and H FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.心脏淀粉样变所致射血分数保留心力衰竭患者的 HFA-PEFF 和 H FPEF 评分的价值。
Eur J Heart Fail. 2022 Dec;24(12):2374-2386. doi: 10.1002/ejhf.2616. Epub 2022 Aug 15.
9
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变的超声心动图参数进展与预后。
Eur J Heart Fail. 2022 Sep;24(9):1700-1712. doi: 10.1002/ejhf.2606. Epub 2022 Jul 27.
10
Endomyocardial biopsy in the clinical context: current indications and challenging scenarios.心肌内膜活检在临床中的应用：当前的适应证和具有挑战性的情况。
Heart Fail Rev. 2023 Jan;28(1):123-135. doi: 10.1007/s10741-022-10247-5. Epub 2022 May 14.
Zotero 插件